Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of BRAF V600 mutation detection on plasma cfDNA in advanced melanoma
2015-001731-20Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cobimetinib in melanoma, sponsored by Roche. Primary endpoint: BRAF V600 mutation status on plasma cfDNA at baseline. Started Feb 2016; status: completed.
02
Drugs
cobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2015-001731-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001731-20.